Voricosis, 200 mg 7 pcs

Voriconazole is a broad-spectrum antifungal agent of the triazole group. The mechanism of action is related to the inhibition of 14α-sterol demethylation mediated through fungal cytochrome P450; this reaction is a key step in ergosterol biosynthesis. Accumulation of 14α-methylsterol correlates with the subsequent loss of ergosterol in fungal cell membranes, which determines the antifungal activity of voriconazole.

Indications

Active ingredient

How to take, the dosage

The drug VORIKOZ (micronized) is administered orally, 1 hour before a meal or 1 hour after a meal. The tablet should be swallowed whole, without chewing, with plenty of water.

Electrolyte disorders such as hypokalemia, hypomagnesemia, and hypocalcemia should be corrected before therapy.

In adults the drug is given on the first day in the recommended saturation dose to achieve plasma concentration of voriconazole close to equilibrium concentration on the first day of therapy.

The indications

Patients with body weight ≥40 kg

Patients with body weight

Saturating dose all indications (first 24 hours) 6 mg/kg every 12 hours intravenous voriconazole for at least 7 days, after which switching to oral medication is possible, provided the patient is able to take oral medication.

Maintenance doses (after the first 24 h)

Prevention of invasive fungal infections in high-risk patients (adults and children over 12 years of age), such as hematopoietic stem cell transplant recipients.

Prevent “breakthrough” fungal infections in febrile patients

200 mg every 12 h

100 mg every 12 h

Invasive aspergillosis, infections caused by Scedosporium spp. and Fusariumspp, other severe invasive fungal infections.

200 mg every 12 h

100 mg every 12 h

Candidaemia in patients without evidence of neutropenia

200 mg every 12 h

100 mg every 12 h

Esophageal candidiasis

200 mg every 12 h

100 mg every 12 h

Interaction

Contraindications

Side effects

The most common adverse reactions were visual disturbances, abnormal liver function test results, fever, rash, vomiting, nausea, diarrhea, headache, peripheral edema, abdominal pain, respiratory depression. The adverse reactions were usually mild to moderate in severity. There was no clinically significant dependence of drug safety on age, race, or sex.

Frequency evaluation criteria: very common ≥10%; common ≥1% and

Cardiac disorders: frequent – supraventricular arrhythmia, tachycardia, bradycardia; infrequent – ventricular fibrillation, ventricular extrasystole, ventricular tachycardia, supraventricular tachycardia; rare – “pirouette” type arrhythmia, complete atrioventricular block, Gis bundle leg block, nodal arrhythmias.

Vascular disorders: often – arterial hypotension, phlebitis; rarely – thrombophlebitis.

Hematopoietic and lymphatic system disorders: frequently – agranulocytosis, pancytopenia, thrombocytopenia, anemia; infrequently – bone marrow depression, leukopenia, lymphadenopathy, eosinophilia, disseminated intravascular coagulation syndrome.

Nervous system disorders: very common Рheadache; common Рsyncope, tremor, dizziness, seizures, nystagmus, paresthesia, somnolence, dizziness; infrequent Рcerebral edema, encephalopathy, extrapyramidal disorder, peripheral neuropathy, ataxia, hypoesthesia, dysgeusia (taste perception disorders); rare Рhepatic encephalopathy, Guienne-Barr̩ syndrome.

VIight: very common – visual disturbances (blurred vision, chromatopsia, photophobia); common – hemorrhage in the retina; infrequent – optic neuritis, edema of the optic disc, oculogyric crisis, scleritis, diplopia, blepharitis; rare – optic atrophy, corneal clouding.

Hearing and vestibular system disorders: infrequent – vertigo, hypoacusis, tinnitus.

Respiratory system, chest and mediastinum disorders: frequently – pulmonary edema, acute respiratory distress syndrome; very frequently – respiratory depression.

Gastro-intestinal disorders: very frequently – nausea, vomiting, diarrhea, abdominal pain; frequently – cheilitis, dyspepsia, constipation; infrequently – duodenitis, glossitis, pancreatitis, tongue swelling.

Renal and urinary tract disorders: frequently – acute renal failure, hematuria; infrequently – renal tubular necrosis, proteinuria, nephritis.

Skin and subcutaneous tissue disorders: very common – rash; common – exfoliative dermatitis, alopecia, skin itching, maculopapular rash, erythema; infrequent – toxic epidermal necrolysis, angioneurotic edema, erythema multiforme, psoriasis, allergic dermatitis, Stevens-Johnson syndrome, photosensitization, urticaria, purpura, papular rash, macular rash, eczema; rare – pseudoporphyria, persistent erythema drug; frequency unknown – cutaneous form of systemic lupus erythematosus.

Musculoskeletal and connective tissue disorders: frequently – back pain; infrequently – arthritis; frequency unknown – periostitis.

Endocrine system disorders: infrequent – insufficiency of the adrenal cortex, hypothyroidism, rarely – hyperthyroidism.

Metabolism and nutrition disorders: very common – peripheral edema, common – hypokalemia, hypoglycemia, hyponatremia (found in post-registration studies).

Infections and invasions: frequently – sinusitis, gastroenteritis, gingivitis; infrequently – pseudomembranous colitis, lymphangitis, peritonitis.

General disorders: very common – pyrexia; common – flu-like illness, chills, asthenia, chest pain, facial edema (periorbital edema, lip edema, mouth edema).

Immune system disorders: infrequent allergic reactions; rarely – anaphylactoid reactions.

Hepatobiliary system disorders: very common – abnormal results of liver function tests, increased activity of aspartate aminotransferase, alanine aminotransferase, alkaline phosphotase, gamma-glutamyltransferase, lactate dehydrogenase, hyperbilirubinemia; common – jaundice, cholestatic jaundice, hepatitis; infrequent – cholecystitis, cholithiasis, increased liver, liver failure.

Mental disorders: frequently hallucinations, depression, anxiety insomnia, agitation, confusion.

New growths benign, malignant and unspecified (including cysts and polyps): frequency unknown – squamous cell skin cancer.

Studies: often – increased concentration of creatinine in blood, infrequently – prolongation of QT interval in electrocardiogram, increased concentration of urea in blood, increased concentration of cholesterol in blood.

Side effects in children

It was found that the adverse effects of the drug in children aged from 3 to 12 years are similar to those in adults. A higher frequency of increased liver enzymes activity was observed in children. Post-registration studies revealed the development of pancreatitis in children on voriconazole therapy, as well as a more frequent occurrence of skin reactions.

Overdose

Pregnancy use

Similarities